Phase 2 trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 agonist) in patients with advanced recurrent EGFR-positive non-small cell lung cancer

References

• Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al, National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005; 353:123 - 32; http://dx.doi.org/10.1056/NEJMoa050753; PMID: 16014882
   PubMed Web of Science ®Google Scholar
• Ray M, Salgia R, Vokes EE. The role of EGFR inhibition in the treatment of non-small cell lung cancer. Oncologist 2009; 14:1116 - 30; http://dx.doi.org/10.1634/theoncologist.2009-0054; PMID: 19892771
   PubMed Web of Science ®Google Scholar
• Krieg AM. Development of TLR9 agonists for cancer therapy. J Clin Invest 2007; 117:1184 - 94; http://dx.doi.org/10.1172/JCI31414; PMID: 17476348
   PubMed Web of Science ®Google Scholar
• Krieg AM. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene 2008; 27:161 - 7; http://dx.doi.org/10.1038/sj.onc.1210911; PMID: 18176597
   PubMed Web of Science ®Google Scholar
• Pashenkov M, Goëss G, Wagner C, Hörmann M, Jandl T, Moser A, et al. Phase II trial of a Toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J Clin Oncol 2006; 24:5716 - 24; http://dx.doi.org/10.1200/JCO.2006.07.9129; PMID: 17179105
   PubMed Web of Science ®Google Scholar
• Kim YH, Girardi M, Duvic M, Kuzel T, Link BK, Pinter-Brown L, et al. Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma. J Am Acad Dermatol 2010; 63:975 - 83; http://dx.doi.org/10.1016/j.jaad.2009.12.052; PMID: 20888065
   PubMed Web of Science ®Google Scholar
• Thompson JA, Kuzel T, Drucker BJ, Urba WJ, Bukowski RM. Safety and efficacy of PF-3512676 for the treatment of stage IV renal cell carcinoma: an open-label, multicenter phase I/II study. Clin Genitourin Cancer 2009; 7:E58 - 65; http://dx.doi.org/10.3816/CGC.2009.n.025; PMID: 19815483
   PubMed Web of Science ®Google Scholar
• Leonard JP, Link BK, Emmanouilides C, Gregory SA, Weisdorf D, Andrey J, et al. Phase I trial of Toll-like receptor 9 agonist PF-3512676 with and following rituximab in patients with recurrent indolent and aggressive non Hodgkin’s lymphoma. Clin Cancer Res 2007; 13:6168 - 74; http://dx.doi.org/10.1158/1078-0432.CCR-07-0815; PMID: 17947483
   PubMed Web of Science ®Google Scholar
• Manegold C, Gravenor D, Woytowitz D, Mezger J, Hirsh V, Albert G, et al. Randomized phase II trial of a Toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer. J Clin Oncol 2008; 26:3979 - 86; http://dx.doi.org/10.1200/JCO.2007.12.5807; PMID: 18711188
   PubMed Web of Science ®Google Scholar
• Hirsh V, Paz-Ares L, Boyer M, Rosell R, Middleton G, Eberhardt WE, et al. Randomized phase III trial of paclitaxel/carboplatin with or without PF-3512676 (Toll-like receptor 9 agonist) as first-line treatment for advanced non-small-cell lung cancer. J Clin Oncol 2011; 29:2667 - 74; http://dx.doi.org/10.1200/JCO.2010.32.8971; PMID: 21632509
   PubMed Web of Science ®Google Scholar
• Manegold C, van Zandwijk N, Szczesna A, Zatloukal P, Au JSK, Blasinska-Morawiec M, et al. A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer. Ann Oncol 2012; 23:72 - 7; http://dx.doi.org/10.1093/annonc/mdr030; PMID: 21464154
   PubMed Web of Science ®Google Scholar
• Belani CP, Nemunaitis JJ, Chachoua A, Eisenberg PD, Raez LE, Cuevas JD, et al. Randomized phase II trial of erlotinib with or without PF-3512676 (CPG 7909, a Toll-like receptor 9 [TLR9] agonist) in patients with advanced recurrent epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer (NSCLC). Presented at: 14th Annual World Conference on Lung Cancer (WCLC) of the International Association for the Study of Lung Cancer (IASLC); July 3-7, 2011; Amsterdam, The Netherlands. Abstract 1167.
   Google Scholar
• U.S. National Institutes of Health. 2nd line erlotinib treatment with (out) chemotherapy of advanced non small cell lung cancer (NSCLC) (NVALT10) (NCT00835471). Available at: http://www.clinicaltrials.gov/ct2/show/NCT00835471?term=erlotinib&recr=Open&rank=13term=erlotinib&recr=Open&rank=3. Accessed December 3, 2012.
   Google Scholar
• U.S. National Institutes of Health. Erlotinib and docetaxel in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) after failure of one chemotherapy regimen (NCT00908336). Available at: http://www.clinicaltrials.gov/ct2/show/NCT00908336?term=erlotinib&recr=Open&rank=21. Accessed December 3, 2012.
   Google Scholar
• U.S. National Institutes of Health. ARQ 197 plus erlotinib versus placebo plus erlotinib for the treatment of non-squamous, non-small-cell lung cancer (NCT01244191). Available at: http://www.clinicaltrials.gov/ct2/show/NCT01244191?term=erlotinib&recr=Open&rank=27. Accessed December 3, 2012.
   Google Scholar
• U.S. National Institutes of Health. Randomized phase II study of AZD6244 MEK-inhibitor with erlotinib in KRAS wild type and KRAS mutant advanced non-small cell lung cancer (NCT01229150). Available at: http://www.clinicaltrials.gov/ct2/show/NCT01229150?term=erlotinib&recr=Open&rank=28. Accessed December 3, 2012.
   Google Scholar
• U.S. National Institutes of Health. Study of oral vinorelbine and erlotinib in non-small cell lung cancer (NCT00702182). Available at: http://www.clinicaltrials.gov/ct2/show/NCT00702182?term=erlotinib&recr=Open&rank=41. Accessed December 3, 2012.
   Google Scholar
• U.S. National Institutes of Health. Study of erlotinib with or without investigational drug (U3-1287) in subjects with advanced non-small cell lung cancer (NCT01211483). Available at: http://www.clinicaltrials.gov/ct2/show/NCT01211483?term=erlotinib&recr=Open&rank=44. Accessed December 3, 2012.
   Google Scholar
• U.S. National Institutes of Health. AMG 102 and erlotinib for advanced non-small cell lung cancer (NCT01233687). Available at: http://www.clinicaltrials.gov/ct2/show/NCT01233687?term=erlotinib&recr=Open&rank=52. Accessed December 3, 2012.
   Google Scholar
• U.S. National Institutes of Health. Study of erlotinib (Tarceva®) in combination with OSI-906 in patients with advanced non-small cell lung carcinoma (NSCLC) with activating mutations of the epidermal growth factor receptor (EGFR) gene (NCT01221077). Available at: http://www.clinicaltrials.gov/ct2/show/NCT01221077?term=erlotinib&recr=Open&rank=3. Accessed December 3, 2012.
   Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205 - 16; http://dx.doi.org/10.1093/jnci/92.3.205; PMID: 10655437
   PubMed Web of Science ®Google Scholar
• U.S. National Institutes of Health. Common terminology criteria for adverse events v3.0 (CTCAE). Available at: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/ctcaev3.pdf. Accessed December 3, 2012.
   Google Scholar